BioNTech looks to sell German vaccine plants as Covid demand fades

BioNTech is in talks with potential buyers to offload manufacturing sites in Germany, the company confirmed. The move shrinks a production network built during the pandemic. BNTX shares fell on the news.

The sites were part of a rapid scale-up in 2020 and 2021, when BioNTech partnered with Pfizer to produce billions of doses of the Comirnaty shot. Vaccine demand collapsed after the public-health emergency ended. Revenue has since dropped more than 90% from peak levels. The manufacturing exit signals management sees no near-term recovery in Covid jab sales.

BioNTech said it has contacted bidders. It did not name them or disclose the number of sites involved. Options include outright sales, joint ventures, or lease transfers. A person familiar with the matter said the talks are at an early stage and could take months to conclude. No deal is guaranteed.

The restructuring targets the fixed-cost base that has weighed on margins. BioNTech spent roughly €1 billion on production capacity in Germany alone during the pandemic, according to its 2021 annual report. Some of that equipment is now idle. Shuttering or selling the sites would reduce annual operating expenses by an unspecified amount, the person said.

Cash from any sale would be directed toward the company's oncology pipeline, BioNTech has previously stated. The firm is developing mRNA-based cancer therapies, including a personalized melanoma vaccine in late-stage trials. The pipeline represents the long-term value thesis for the stock. The timeline to revenue is uncertain – the melanoma candidate is not expected to launch before 2026.

BioNTech's Alpha Score of 38 is labeled Mixed, reflecting a stock caught between fading near-term earnings and a speculative pipeline. Balance-sheet cash provides a floor. The absence of a clear catalyst for the oncology story keeps the risk profile elevated.

The manufacturing talks follow a broader industry trend. Moderna announced similar capacity reductions last year. Pfizer idled its own German plant in 2023. BioNTech's move suggests the post-pandemic normalization is still running its course. For a company that became a household name overnight, the retreat from manufacturing marks a return to its pre-2020 identity: a biotech company, not a mass producer.

The next catalyst for the stock is likely the second-quarter earnings report. Analysts will press management for specifics on the site sale timeline and the associated cost savings. Until those details emerge, the market will treat the restructuring as a work in progress.